Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
IPO Date: October 5, 2001
Sector: Healthcare
Industry: Biotech
Market Cap: $2.69B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.13 | 3.28%
Avg Daily Range (30 D): $0.49 | 2.13%
Avg Daily Range (90 D): $0.43 | 1.96%
Institutional Daily Volume
Avg Daily Volume: .83M
Avg Daily Volume (30 D): 1.05M
Avg Daily Volume (90 D): .92M
Trade Size
Avg Trade Size (Sh.): 156
Avg Trade Size (Sh.) (30 D): 58
Avg Trade Size (Sh.) (90 D): 59
Institutional Trades
Total Inst.Trades: 1,988
Avg Inst. Trade: $2.67M
Avg Inst. Trade (30 D): $3.55M
Avg Inst. Trade (90 D): $3.5M
Avg Inst. Trade Volume: .23M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $3.34M
Avg Closing Trade (30 D): $6.51M
Avg Closing Trade (90 D): $5.6M
Avg Closing Volume: 280.15K
       
News
Mar 24, 2025 @ 6:00 AM
Santhera to share latest on commercial rollout of ...
Source: N/A
Jun 7, 2024 @ 3:30 PM
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings...
Source: Zacks Equity Research
Jun 3, 2024 @ 1:00 PM
A Closer Look at 7 Analyst Recommendations For Cat...
Source: Benzinga Insights
May 30, 2024 @ 5:41 PM
Catalyst Pharmaceuticals Receives U.S. FDA Approva...
Source: Catalyst Pharmaceuticals, Inc.
May 28, 2024 @ 12:03 PM
Catalyst Pharmaceuticals to Participate at the Jef...
Source: Catalyst Pharmaceuticals, Inc.
Financials
  TTM Q4 2024 FY 2024
Basic EPS $1.38 $.46 $1.38
Diluted EPS $1.31 $.44 $1.31
Revenue $ 491.73M $ 141.82M $ 491.73M
Gross Profit $ 422.89M $ 120.18M $ 422.89M
Net Income / Loss $ 163.89M $ 55.94M $ 163.89M
Operating Income / Loss $ 195.12M $ 62.84M $ 195.12M
Cost of Revenue $ 68.85M $ 21.64M $ 68.85M
Net Cash Flow $ 379.92M $ 75.22M $ 379.92M
PE Ratio 0.00